April 1st 2025
Family physician and researcher Mark Ebell, MD, discusses the clinical implications, efficacy, and role of gepotidacin in UTI management.
FDA Approves GSK Vaccine Arexvy for Prevention of RSV in High-Risk Adults Aged 50 to 59 Years
June 7th 2024GSK announced today approval by the US FDA of a label expansion for the adjuvanted RSV vaccine that adds adults aged 50 to 59 years who are at elevated risk for RSV disease to the vaccine’s current indication.